ISRCTN37915093已完成未知
The impact of Hepatitis C viral load determined short-course treatment vs fixed duration treatment on Hepatitis C cure for patients with mild genotype-1 Hepatitis C disease
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 202
研究概览
简要总结
2021 Results article in https://pubmed.ncbi.nlm.nih.gov/34405118/ (added 19/08/2021) 2021 Results article in https://pubmed.ncbi.nlm.nih.gov/34723451/ (added 19/05/2023)
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Aged =18 years
- •2. Infected with HCV genotype 1a or 1b with HCV RNA >LLOQ (lower limit of quantification) on more than one occasion at least six months previously with no intervening results showing undetectable viraemia
- •3. Plasma HCV RNA >LLOQ at screening
- •4. No evidence of significant liver fibrosis resulting from any aetiology (defined as Fibroscan* score =7.1kPa, equivalent to F0-F134, within 180 days prior to planned randomisation or biopsy consistent with mild fibrosis (Ishak score <=2/6) within 180 days prior to planned randomisation)
- •5. BMI >=18kg/m2
- •6. Laboratory tests: platelets >=60x109/l, haemoglobin >12g/dl (male) or >11g/dl (female), creatinine clearance (estimated glomerular filtration rate (eGFR) (Cockcroft-Gault)) >=60ml/min, international normalised ratio (INR) <1.5xULN
- •7. Screening HCV viral load <10,000,000IU/ml
- •8. Written informed consent obtained from the patient
- •If HIV infected, then an additional eligibility criteria is:
- •9. On antiretroviral therapy with HIV viral load <50 copies/ml for >24 weeks at the screening visit
排除标准
- •1. Previous direct acting antivirals (DAA) exposure (previous treatment with pegylated-interferon and/or ribavirin allowed)
- •2. Malignancy within 5 years prior to screening
- •3. Any condition in the judgement of the investigator which might limit the patient’s life expectancy
- •4. Currently receiving medication know to interact with study medication (ombitasvir, paritaprevir, dasabuvir, ritonavir, sofosbuvir, ledipasvir, ribavirin; see relevant prescribing information
- •8. Disorder which may cause ongoing liver disease including, but not limited to, active hepatitis B, ongoing alcohol misuse
- •5. Any disorder which in the opinion of the investigator may have a significant negative impact on the ability of the patient to adhere to the trial regimen
- •6. Use of other investigational products within 60 days of screening
- •7. Known hypersensitivity to any active ingredient and/or excipients of the study medicines, namely Microcrystalline cellulose, Lactose monohydrate, Croscarmellose sodium, Magnesium stearate, Gelatine, Shellac, Propylene glycol, Polyethylene glycol, Ammonium hydroxide, Pregelatinised maize starch, Sodium starch glycolate (type A), Maize starch, Hypromellose, Talc, Ethylcellulose aqueous dispersion, Triacetin, Copovidone, Colloidal anhydrous silica, Polyvinyl alcohol, Macrogol 3350, Sunset yellow FCF aluminium lake (E110), Colouring agent (E132), Titanium dioxide (E171), Yellow iron oxide (E172), Red iron oxide (E172), Black iron oxide (E172).
- •8. History of severe pre-existing cardiac disease, including unstable or uncontrolled cardiac disease, in the previous six months
- •9. Haemoglobinopathies (e.g., thalassemia, sickle-cell anaemia)
- •Female participants only:
- •1. Lactating, or pregnant, or planning to become pregnant during the study or within 4 months of the end of the study, or not willing to use effective contraception during the study and for four months after last dose of study medication
- •2. Currently taking ethinyl-oestradiol-containing medicinal products such as those contained in most combined oral contraceptives or contraceptive vaginal rings
- •Male participants only:
- •Planning pregnancy with female partner during the study or within 7 months of the end of the study, or not willing to use effective contraception during the study and for seven months after last dose of study medication
研究者
相似试验
进行中（未招募）
不适用
What is the impact of antiviral treatment for people who inject drugs on the overall number of new hepatitis C infections within the population of injecting drug users?Hepatitis CInfections and InfestationsChronic viral hepatitis CISRCTN72038467niversity of Dundee555
已完成
不适用
Hepatitis C Rimantadine and Antiviral Combination TherapyHepatitis CNCT01413490The Leeds Teaching Hospitals NHS Trust10
终止
不适用
Impact of Hepatitis C Virus Variability on SteatosisChronic Hepatitis CNCT00843076University Hospital, Tours27
Unknown
不适用
Impact of Sustained Virologic Response on Glycemic Control Among Diabetic Patients With Hepatitis C Virus Related Liver DiseaseHepatitis cNCT03591783Assiut University140
已完成
不适用
A Cross Sectional Observational Study on Relation Between Oral Manifestation and Hepatitis C in EgyptOral ManifestationsHepatitis Cin Egyptian PopulationNCT04812990Misr University for Science and Technology100